It has been confirmed that Isu Abzys and Binex have already signed a business agreement (MOU) for 150 million dose consignment production (CMO) of Russia’s novel coronavirus infection (Corona 19) vaccine’Sputnik V’.
The industry is expecting Russian officials to complete the due diligence next week and sign this contract.
On the 10th, an official from Isu Abgis said, “We have already signed an MOU for consignment production of Sputnik V at the beginning of the week.”
He added, “The quantity and schedule of this contract are confidentiality agreement (NDA) provisions.”
Russia’s vaccine Sputnik V, which had not received much attention even at the beginning of its launch, is emerging as an alternative as European countries are suffering from a lack of vaccine.
Recently, Lancet, an international medical journal, published a Phase III result that Sputnik V’s immune effect reached 91.6%, and the effect on the elderly over the age of 60 reached 91.8%.
It is currently used in Mexico, Iran, Palestine, etc., but the number of countries that approve the use continues to increase. On the 9th, Pakistan and Mongolia approved emergency use of Sputnik V for the 22nd and 23rd in the world.
The possibility of use in Europe is also increasing, as Germany and Russia announced that they would also prospectively review the introduction of the vaccine, followed by voices that Italy should also loosen the barrier.
There is a position of health authorities saying that the introduction of Russian vaccines in Korea can also be considered.
The Russian vaccine Sputnik V initially signed a production contract with the Korean Chorus. However, it is known that only a small amount of vaccines are currently produced due to insufficient bioreactors for production.
Accordingly, it is said that the Russian side has joined hands with Isu Abgis and Binex among companies that can be mass-consigned.
Binex, a CMO company, as well as ISU Abgis, have a vaccine production line among their production plants, capable of producing 150 million doses.
In the industry, it is reported that officials from Russia’s Sputnik V development company will visit ISU Abgis and Binex.
Heo Hye-min, a researcher at Kiwoom Securities, said, “If you become the CMO for Sputnik vaccine, you will get know-how and positive results based on this,” he said. “Based on this, we can expect vitality to win additional CDMO orders.”